A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration

NCT01755494 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus(T2DM)

Interventions

DRUG: Saxagliptin 5 mg
DRUG: Metformin XR 500 mg
DRUG: Mertformin XR 2 x 500 mg
DRUG: Komboglyze XR 5/500 mg
DRUG: Komboglyze XR 5/1000 mg

Sponsor

AstraZeneca

Collaborators

[object Object]